Brain Advance Access published online on December 9, 2005
Brain, doi:10.1093/brain/awh703
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany; Section of Experimental Neurosurgery, Department of Neurosurgery, University of Würzburg, Würzburg, Germany
* To whom correspondence should be addressed. In humans, neurotrauma is suspected to cause brain atrophy and accelerate slowly progressive neurodegenerative disorders, such as Alzheimer's disease or schizophrenia. However, a direct link between brain injury and subsequent delayed global neurodegeneration has remained elusive. Here we show that juvenile (4-week-old) mice that are given a discrete unilateral lesion of the parietal cortex, develop to adulthood without obvious clinical symptoms. However, when monitored 3 and 9 months after lesioning, using high-resolution three-dimensional MRI and behavioural testing, the same mice display global neurodegenerative changes. Surprisingly, erythropoietin, a haematopoietic growth factor with potent neuroprotective activity, prevents behavioural abnormalities, cognitive dysfunction and brain atrophy when given for 2 weeks after acute brain injury. This demonstrates that a localized brain lesion is a primary cause of delayed global neurodegeneration that can be efficiently counteracted by neuroprotection.
Received July 1, 2005
Revised September 26, 2005
Accepted October 27, 2005
Article
Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin
Anna-Leena Sirén 1,
Konstantin Radyushkin 2,
Susann Boretius 3,
Daniel Kämmer 4,
Claas-Christian Riechers 4,
Oliver Natt 3,
Derya Sargin 4,
Takashi Watanabe 3,
Swetlana Sperling 4,
Thomas Michaelis 3,
Jack Price 5,
Barbara Meyer 6,
Jens Frahm 3,
and
Hannelore Ehrenreich 4 *
2 Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany; Department of Molecular Cell Biology, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
3 Biomedizinische NMR Forschungs GmbH, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
4 Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany
5 Institute of Psychiatry, King's College London, London, UK
6 Department of Molecular Cell Biology, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
Hannelore Ehrenreich, E-mail: ehrenreich{at}em.mpg.de
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H. Ehrenreich, B. Fischer, C. Norra, F. Schellenberger, N. Stender, M. Stiefel, A.-L. Siren, W. Paulus, K.-A. Nave, R. Gold, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis Brain, October 1, 2007; 130(10): 2577 - 2588. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ehrenreich, D. Hinze-Selch, S. Stawicki, C. Aust, S. Knolle-Veentjer, S. Wilms, G. Heinz, S. Erdag, H. Jahn, D. Degner, et al. Hemoglobin-Independent Organ Protection by EPO in Humans: Amelioration of Cognitive Loss in Chronic Schizophrenia J. Am. Soc. Nephrol., January 1, 2007; 18(1): 3 - 6. [Abstract] [Full Text] [PDF] |
||||

